用于检测结直肠癌组织和血清中甲基化 SFRP2 DNA 的 MethyLight 检测方法的性能。

Performance of a MethyLight assay for methylated SFRP2 DNA detection in colorectal cancer tissue and serum.

机构信息

1 Department of Gastroenterology, Affiliated Hospital of Xuzhou Medical University, Xuzhou Jiangsu, China.

2 School of Medical Technology, Xuzhou Medical University, Xuzhou Jiangsu, China.

出版信息

Int J Biol Markers. 2019 Mar;34(1):54-59. doi: 10.1177/1724600818820536. Epub 2019 Mar 11.

DOI:10.1177/1724600818820536

PMID:30852954

Abstract

BACKGROUND

Colorectal cancer is one of the five most common cancers in China, and its incidence is steadily increasing. An accurate and non-invasive screening method is needed to increase the population uptake of colorectal cancer screening. Secreted frizzled-related protein 2 ( SFRP2) has been found to be hypermethylated in most colorectal cancer patients, and it may fulfill the role of a non-invasive biomarker for colorectal cancer screening.

METHODS

Methylation status of SFRP2 was examined in 17 cancer tissues and paired adjacent paracancer tissues by a new SFRP2 MethyLight assay, which was also used to test the serum of 62 patients with colorectal cancer and 55 normal individuals.

RESULTS

The limit of detection of the SFRP2 MethyLight assay was about 200 pg per reaction. The SFRP2 methylation level was higher in 94.1% colorectal cancer tissues than in paired adjacent paracancer tissues ( P<0.001). The sensitivity and specificity of SFRP2 for detecting colorectal cancer in serum were 69.4% (95% confidence interval (CI) 56.2, 80.1%) and 87.3% (95% CI 74.9, 94.3%), respectively.

CONCLUSION

SFRP2 methylation in serum has the potential to be a non-invasive biomarker for colorectal cancer screening.

摘要

背景

结直肠癌是中国最常见的五种癌症之一，其发病率呈稳步上升趋势。需要一种准确且非侵入性的筛选方法来提高结直肠癌筛查的人群参与率。已发现分泌卷曲相关蛋白 2（SFRP2）在大多数结直肠癌患者中呈高甲基化状态，它可能作为结直肠癌筛查的非侵入性生物标志物发挥作用。

方法

采用新的 SFRP2 MethyLight 检测法检测 17 例癌组织和配对的癌旁组织中 SFRP2 的甲基化状态，并检测 62 例结直肠癌患者和 55 例正常人的血清。

结果

SFRP2 MethyLight 检测法的检测限约为 200 pg/反应。94.1%的结直肠癌组织中 SFRP2 的甲基化水平高于配对的癌旁组织（P<0.001）。SFRP2 对血清中结直肠癌的检测灵敏度和特异性分别为 69.4%（95%置信区间 56.2%，80.1%）和 87.3%（95%置信区间 74.9%，94.3%）。